 |
Find a Stock's Home Page |
|
| News |
San Diego, CA 7/09/2009
Electro-Optical Sciences, Inc. (MELA) investors, as it stands right now, should be able to celebrate in December. The company's light-based device called a MelaFind has been 'fast-tracked' by the FDA, which means it could be approved for sale as early as December of this year (assuming nothing unexpected surfaces).
Investors and traders are invited to read further analytical review of Electro-Optical Sciences, Inc. as well as similar opportunities by subscribing to the free Small Cap Network Newsletter, which offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: access.smallcapnetwork.com/s/.
Electro-Optical Sciences, Inc. recently announced that the company's shares have been added to the Russell 2000(r) and Russell 3000(r) indexes, effective as of June 29th.
About Electro-Optical Sciences, Inc.
Electro-Optical Sciences, Inc. (MELA) is a medical technology company focused on developing MelaFind, a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. EOS designed MelaFind to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. For more information on EOS, visit www.eosciences.com.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Four-Small-Cap-Biotechs-FDA-Favors-Two-Denies-Two/s/article/view/p/mid/1/id/134/
